10,309 Shares in Medpace Holdings, Inc. $MEDP Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

Key Points

• Virginia Retirement Systems purchased 10,309 Medpace shares worth approximately $5.46 million in the second quarter, while institutional investors overall own 77.98% of the company.
• Analysts remain cautious, with three Buy ratings and nine Holds; Medpace has an average rating of Hold and an average price target of $595.20.
• Medpace reported strong quarterly results, with revenue rising 17.2% year over year to $707.33 million and EPS of $4.25, beating estimates of $3.98. Meanwhile, insiders have sold about $82.2 million of stock over the past 90 days.

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,309 shares of the company's stock, valued at approximately $5,460,000.

Several other institutional investors also recently made changes to their positions in MEDP. Johnson Financial Group Inc. purchased a new position in shares of Medpace in the 2nd quarter valued at about $27,000. Elyxium Wealth LLC purchased a new stake in Medpace during the fourth quarter worth about $30,000. Jones Financial Companies Lllp acquired a new position in Medpace during the second quarter worth about $30,000. Allied Private Wealth LLC purchased a new position in Medpace in the second quarter valued at about $31,000. Finally, Kilter Group LLC purchased a new position in Medpace in the second quarter valued at about $31,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MEDP. Jefferies Financial Group downgraded Medpace from a "buy" rating to a "hold" rating and raised their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Truist Financial raised their price target on Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a research report on Friday, July 24th. BMO Capital Markets lifted their price target on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research note on Friday, July 24th. Royal Bank Of Canada boosted their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Finally, TD Cowen increased their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, Medpace presently has an average rating of "Hold" and an average target price of $595.20.

Insider Activity

In related news, CEO August J. Troendle sold 650 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $620.27, for a total transaction of $403,175.50. Following the sale, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the sale, the director directly owned 27,825 shares of the company's stock, valued at $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 134,471 shares of company stock valued at $82,151,311. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Performance

Medpace stock opened at $590.89 on Wednesday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The company has a market capitalization of $16.49 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 2.64 and a beta of 1.15. The stock has a fifty day moving average of $577.04 and a two-hundred day moving average of $502.19.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the company earned $3.10 earnings per share. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.